About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

A 3-day Course for CFS/ME | Clinical Trials | Clareo Health

Back to clinical trial search

RECRUITINGNANCT05236465

A 3-day Course for CFS/ME

Chronic fatigue syndrome/Myalgic encephalomyelitis (CFS/ME) can be a serious and disabling condition with a heavy symptom burden and low function. Work disability is common, and social life dramatical...

Lead sponsor: Norwegian University of Science and Technology•1 locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Clareo turns complex medical information into clear understanding you can use.

Bring this clarity to your next appointment.

Keep all your medical notes and next steps in one place.

Contacts

Leif Edward Ottesen Kennair, PhD prof

CONTACT

+47 90557004 kennair@ntnu.no

Live Landmark

CONTACT

+47 91855303 Livelan@stud.ntnu.no

Sponsors

Lead Sponsor

Norwegian University of Science and Technology

Collaborators

University of Oslo
Haukeland University Hospital
Lørenskog municipality
The Research Council of Norway

This is a randomized controlled trial (RCT) to investigate potential effects (positive and negative) of a 3-day course with follow-up for 100 adults with CFS/ME. The 3-day course used in this trial is named the Lightning Process (LP). The course is built on the LP manual (Parker, 2013) and includes stress theory, Positive Psychology and knowledge about regulating thoughts, feelings and behavior, and through that positively influencing physiology. Positive and negative effects of the course on symptoms, disability and quality of life will be investigated, and a long-term follow-up of work participation conducted. Any adverse events experienced during or after the 3-day course will be handled according to protocol.

Age

18 - 65 years

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•CFS/ME diagnosis based on the Canada Consensus Criteria.
•At least 50% out of school/work.
•Readiness to change (corresponding to the preparation phase in transtheoretical model)
•Has given informed consent.

Exclusion Criteria

•Assessed by a General Practitioner (GP):
•Underlying physical illness or mental disorder that may explain the symptoms.
•Suicide risk/previous suicide attempts.
•Pregnancy.
•Bedridden and in need of continuous care.
•Insufficient Norwegian speaking or writing skills to participate in the 3-day course and fill out questionnaires.

Related studies

RECRUITINGPhase 1/2

Lumbrokinase for Adults With Long Covid, Post-treatment Lyme Disease Syndrome, and Myalgic Encephalomyelitis/Chronic Fatigue Syndrome

NCT06511050 · Long Covid, Post-treatment Lyme Disease Syndrome, and more

RECRUITINGPhase 2

Assessment of N-Acetylcysteine as Therapy for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome

NCT04542161 · Chronic Fatigue Syndrome, Myalgic Encephalomyelitis

RECRUITINGPhase 1

Assessment of Neuroinflammation in Central Inflammatory Disorders Using [F-18]DPA-714.

NCT03759522 · Fibromyalgia, Chronic Fatigue Syndrome, and more

Unhide® Project: A Digital Health Platform to Collect Lifestyle Data for Brain Inflammation Research

NCT04806620 · Post-Acute COVID-19 Syndrome, ME/CFS, and more

RECRUITINGPhase 2

Study of the Efficacy and Safety for Rituximab in Myalgia Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS)

NCT06952413 · Myalgia Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS)

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: November 26, 2025Terms

Trial snapshot

StatusRECRUITING

PhaseNA

Enrollment100

Start dateMar 2022

Last updatedNov 26, 2025

Condition

Chronic Fatigue Syndrome Myalgic Encephalomyelitis

Locations shown

Department of Psychology, NTNU

Trondheim

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: November 26, 2025Data synced to Clareo: May 10, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions